Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
39 hedge funds and large institutions have $67.2M invested in Viracta Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 8 closing their positions.
26,455% more call options, than puts
Call options by funds: $37.4M | Put options by funds: $141K
165% more capital invested
Capital invested by funds: $25.4M → $67.2M (+$41.8M)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
11% more funds holding
Funds holding: 35 → 39 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.29M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$6.03M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$1.21M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.1M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$803K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.83M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$318K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$217K |
| 4 |
Renaissance Technologies
New York
|
-$144K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$130K |
VIRX Hedge Fund Activity: Q4 2017 in Review
39 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2017, worth a combined $67.2M — up 165% from $25.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VIRX positions and 8 closed out — a net gain of 4 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $8.29M. The largest seller was Great Point Partners, exiting entirely with an estimated $2.83M sold.
- 39 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2017, up from 35 in Q3 2017.
- Funds reported $67.2M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2017, up 165% quarter-over-quarter.
- 12 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2017 and 8 closed out, a net change of +4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2017 was RA Capital Management, an estimated $8.29M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2017 was Great Point Partners, an estimated $2.83M sold.
Based on aggregated 13F filings for Q4 2017.